BUSRA ACAR

Ms. BUSRA ACAR

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2024 in Pharmaceuticals
Verified
Journal Article
Open access
TATugba Ucar Akyürek
Tugba Ucar Akyürek
Ilkay Erdogan OrhanIlkay Erdogan Orhan
Ilkay Erdogan Orhan
Fatma Sezer Senol DenizFatma Sezer Senol Deniz
Fatma Sezer Senol Deniz
GEGokcen Eren
Gokcen Eren
BABUSRA ACAR
BUSRA ACAR
ASAlaattin SEN
Alaattin SEN
Background: The goal of the current study was to investigate the inhibitory activity of six phenolic compounds, i.e., rosmarinic acid, gallic acid, oleuropein, epigallocatechin gallate (EGCG), 3-hydroxytyrosol, and quercetin, against β-site amyloid precursor protein cleaving enzyme-1 (BACE1), also known as β-secretase or memapsin 2, which is implicated in the pathogenesis of Alzheimer’s disease (AD). Methods and Results: The inhibitory potential against BACE1, molecular docking simulations, as well as neurotoxicity and the effect on the AD-related gene expression of the selected phenolics were tested. BACE1 inhibitory activity was carried out using the ELISA microplate assay via fluorescence resonance energy transfer (FRET) technology. Molecular docking experiments were performed in the human BACE1 active site (PDB code: 2WJO). Neurotoxicity of the compounds was carried out in SH-SY5Y, a human neuroblastoma cell line, by the Alamar Blue method. A gene expression analysis of the compounds on fourteen genes linked to AD was conducted using the real-time polymerase chain reaction (RT-PCR) method. Rosmarinic acid, EGCG, oleuropein, and quercetin (also used as the reference) were able to inhibit BACE1 with their respective IC50 values 4.06 ± 0.68, 1.62 ± 0.12, 9.87 ± 1.01, and 3.16 ± 0.30 mM. The inhibitory compounds were observed to occupy the non-catalytic site of the BACE1. However, hydrogen bonds were found to be present between rosmarinic acid and EGCG and aspartic amino acid D228 in the catalytic site. Oleuropein and quercetin effectively suppressed the expression of PSEN, APOE, and CLU, which are recognized to be linked to the pathogenesis of AD. Conclusions: The outcomes of the work bring quercetin, EGCG, and rosmarinic acid to the forefront as promising BACE1 inhibitors.

3 September 2025 in Archiv der Pharmazie
Verified
Journal Article
Closed access
NPNihan Aktaş Pepe
Nihan Aktaş Pepe
FÇFurkan Çakır
Furkan Çakır
TATuğba Atalay
Tuğba Atalay
BABUSRA ACAR
BUSRA ACAR
GTGurbet Çelik Turgut
Gurbet Çelik Turgut
HŞHalil ŞENOL
Halil ŞENOL

29 October 2025 in ChemistrySelect
Verified
Journal Article
Closed access
NPNihan Aktaş Pepe
Nihan Aktaş Pepe
BABUSRA ACAR
BUSRA ACAR
YEYağmur Ceylan Ekiz
Yağmur Ceylan Ekiz
AŞAyşe Merve Şenol
Ayşe Merve Şenol
GSGürkan Semiz
Gürkan Semiz
GTGurbet Celik Turgut
Gurbet Celik Turgut

29 April 2025 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
NPNihan Aktaş Pepe
Nihan Aktaş Pepe
BABUSRA ACAR
BUSRA ACAR
GZGozde Erturk Zararsiz
Gozde Erturk Zararsiz
SASerife Ayaz-Guner
Serife Ayaz-Guner
ASAlaattin SEN
Alaattin SEN
Background/Objectives: X-inactive-specific transcript (XIST) is a factor that plays a role in neuroinflammation. This study investigated the role of XIST in neuronal development, neuroinflammation, myelination, and therapeutic responses within cerebral organoids in the context of Multiple Sclerosis (MS) pathogenesis. Methods: Human cerebral organoids with oligodendrocytes were produced from XIST-silenced H9 cells, and the mature organoids were subsequently treated with either FTY720 or DMF. Gene expression related to inflammation and myelination was subsequently analyzed via qRT-PCR. Immunofluorescence staining was used to assess the expression of proteins related to inflammation, myelination, and neuronal differentiation. Alpha-synuclein protein levels were also checked via ELISA. Finally, transcriptome analysis was conducted on the organoid samples. Results: XIST-silenced organoids presented a 2-fold increase in the expression of neuronal stem cells, excitatory neurons, microglia, and mature oligodendrocyte markers. In addition, XIST silencing increased IL-10 mRNA expression by 2-fold and MBP and PLP1 expression by 2.3- and 0.6-fold, respectively. Although XIST silencing tripled IBA1 protein expression, it did not affect organoid MBP expression. FTY720, but not DMF, distinguished MBP and IBA1 expression in XIST-silenced organoids. Furthermore, XIST silencing reduced the concentration of alpha-synuclein from 300 to 100 pg/mL, confirming its anti-inflammatory role. Transcriptomic and gene enrichment analyses revealed that the differentially expressed genes are involved in neural development and immune processes, suggesting the role of XIST in neuroinflammation. The silencing of XIST modified the expression of genes associated with inflammation, myelination, and neuronal growth in cerebral organoids, indicating a potential involvement in the pathogenesis of MS. Conclusions: XIST may contribute to the MS pathogenesis as well as neuroinflammatory diseases such as and Alzheimer’s and Parkinson’s diseases and may be a promising therapeutic target.